Tyra Biosciences

OverviewSuggest Edit

Tyra Biosciences is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance. The company develops a proprietary SNÅP platform to identify and selectively target vulnerabilities in mutant proteins. Its product candidates include the FGFR3 program—TYRA-300, the FGFR2 program, as well as the achondroplasia, RET, and FGFR4 programs.
HQCarlsbad, CA, US

Latest Updates

Employees (est.) (Sept 2021)16(-11%)
Share Price (Jan 2022)$12.5(+2%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Tyra Biosciences

Todd Harris

Todd Harris

Chief Executive Officer
John Healy

John Healy

General Counsel
Robert L. Hudkins

Robert L. Hudkins

Chief Technology Officer
Piyush Patel

Piyush Patel

Chief Development Officer
Daniel Bensen

Daniel Bensen

Chief Operating Officer
Ronald V. Swanson

Ronald V. Swanson

Chief Scientific Officer
Show more

Tyra Biosciences Office Locations

Tyra Biosciences has an office in Carlsbad
Carlsbad, CA, US (HQ)
2656 State St
Show all (1)

Tyra Biosciences Financials and Metrics

Summary Metrics

Founding Date


Tyra Biosciences total Funding

$156 m

Tyra Biosciences latest funding size

$106 m

Time since last funding

10 months ago

Tyra Biosciences investors

Tyra Biosciences's latest funding round in March 2021 was reported to be $106 m. In total, Tyra Biosciences has raised $156 m
Show all financial metrics

Tyra Biosciences Online and Social Media Presence

Embed Graph

Tyra Biosciences News and Updates

Tyra Biosciences stock soars more than 60% on public debut

Shares of oncology biotech company Tyra Biosciences jumped more than 60% on their first day of trading Wednesday. Tyra raised $173 million by offering 10.8 million shares at $16, at the high end of expectations between $14 and $16 and an upsized deal. Tyra is one of several newly minted companies t…

Tyra Biosciences upsizes IPO to 9 million shares vs. prior 6.7 million for valuation of up to $626 million

Tyra Biosciences Inc. upsized its planned initial public offering on Tuesday to 9 million share from an earlier plan to offer 6.7 million. The company would raise $144 million at the top of that range at a valuation of $626 million. The biotech's leading product candidate is a treatment for bladder…

Tyra Biosciences Frequently Asked Questions

  • When was Tyra Biosciences founded?

    Tyra Biosciences was founded in 2018.

  • Who are Tyra Biosciences key executives?

    Tyra Biosciences's key executives are Todd Harris, John Healy and Robert L. Hudkins.

  • How many employees does Tyra Biosciences have?

    Tyra Biosciences has 16 employees.

  • Who are Tyra Biosciences competitors?

    Competitors of Tyra Biosciences include Scorpion Therapeutics, HiberCell and BioNTech.

  • Where is Tyra Biosciences headquarters?

    Tyra Biosciences headquarters is located at 2656 State St, Carlsbad.

  • Where are Tyra Biosciences offices?

    Tyra Biosciences has an office in Carlsbad.

  • How many offices does Tyra Biosciences have?

    Tyra Biosciences has 1 office.